Mesoblast Limited develops regenerative medicine therapies based on mesenchymal lineage cells, a proprietary technology platform. The company's lead candidate, Remestemcel-L, is in Phase III clinical trials for multiple indications including steroid-refractory acute graft versus host disease, biologic-refractory inflammatory bowel disease, ulcerative colitis, Crohn's disease, chronic heart failure, and chronic low back pain due to degenerative disc disease. The company is also advancing MPC-300-IV for biologic-refractory rheumatoid arthritis and diabetic nephropathy.
Mesoblast operates through partnerships that extend its commercial reach. Tasly Pharmaceutical Group licenses candidates for chronic heart failure, acute myocardial infarction, and pediatric steroid-refractory acute graft versus host disease under the Ryoncil brand. JCR Pharmaceuticals Co. Ltd. holds rights to develop therapies for epidermolysis bullosa wound healing and neonatal hypoxic ischemic encephalopathy. Grünenthal partners on cell therapy development for chronic low back pain.
The company maintains operations across Australia, the United States, Singapore, and Switzerland with 81 full-time employees. Mesoblast was incorporated in 2004 and is headquartered in Melbourne, Australia, with listings on Nasdaq.
No 10-K filings found.